ArticleCureus2021
Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Multiple primary head and neck cancers: a scenario-based framework for diagnosis and modern multidisciplinary management.Frontiers in oncology · 2026Pooled it
- Diagnostic Challenge of Contralateral Intranodal Thyroid Inclusions in a Patient With Synchronous Oropharyngeal and Papillary Thyroid Carcinoma: A Case Report.Clinical case reports · 2026Article
- NOC4L: An Emerging Dual-Action Target for Cancer Prognosis and Immunotherapy.Applied biochemistry and biotechnology · 2026Article
- ATP6V1B2 Regulating Autophagy Flux To Affect Abnormal Auditory Development.Applied biochemistry and biotechnology · 2026Article
- Article
- Multi-omics characterization of benzo[a]pyrene toxicity networks identifies SERPINE1 and STK3 as prognostic biomarkers and therapeutic targets in head and neck squamous cell carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dual primary malignancies in Kashmir: A five-year analysis of temporal patterns, gender-specific presentations and treatment outcomes in a high gastrointestinal cancer risk population.Journal of family medicine and primary care · 2026Review
- Anticancer Molecular Mechanisms of Phytosterols: An Updated Review on Clinical Trials.Food science & nutrition · 2026Review
- The MALDI Method to Analyze the Lipid Profile, Including Cholesterol, Triglycerides and Other Lipids.Current issues in molecular biology · 2026Review
- Neuroprotective effects of Ershiwuwei Shanhu pills on APP/PS1 mice through antioxidant enhancement, anti-apoptosis, and MAPK pathway regulation.Translational neuroscience · 2026Article
- Genetic and Molecular Determinants of Immunotherapy Response in Recurrent Ovarian Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Case Report: A case of superficial spreading malignant melanoma with sentinel lymph node metastasis misdiagnosed as "pigmented nevus".Frontiers in immunology · 2026Article
- Diagnostics and monitoring in Hymenoptera venom allergy: current and future perspectives.Frontiers in allergy · 2026Review
- Plasma proteome-wide Mendelian randomization reveals multi-ancestry drug targets for gastric cancer.Frontiers in oncology · 2026Article
- From gut-reproductive microbiota to ferroptosis: a comprehensive insight into the molecular-pathogenicity of endometriosis.Frontiers in immunology · 2026Review
- Microbiological Investigation and Clinical Efficacy of Professional Topical Fluoride Application onMicroorganisms · 2025Article
- Article
- Notoginsenoside R1 Improved Hypoxic Pulmonary Hypertension by Inhibiting Glycolysis-Mediated Pulmonary Arterial Vascular Remodeling.Canadian respiratory journal · 2025Article
- The key role of the ferroptosis mechanism in neurological diseases and prospects for targeted therapy.Frontiers in neuroscience · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction With an estimated incidence of 2%-4% per year, the development of a second primary malignancy (SPM) in patients with head and neck tumors (HNTs) is not a rare event. The present study aimed to (i) assess the frequency of SPMs in patients with HNTs treated in a university hospital over a five-year period and (ii) provide a demographic characterization of these patients. Methods Retrospective single-centre study of patients with more than one primary tumor (including at least one HNT) diagnosed between January 1, 2015, and December 31, 2019. Data were retrieved from patients' clinical records and anonymized for analysis purposes. Results A total of 53 out of 824 (6.43%) patients with multiple primary malignancies were identified, 18 of which synchronous and 35 metachronous. The median follow-up was 25 months. Thirteen patients were diagnosed with more than one HNT. Forty patients were diagnosed with at least one HNT and one non-HNT. The most frequently diagnosed non-HNT SPMs were lung cancer (n=17) and esophageal cancer (n=8). The five-year survival rate was 53% for patients with multiple HNSCCs and 47% for patients with at least one non-HNT (log-rank p=0.729). The median overall survival was 14 months for synchronous and 58 months for metachronous SPMs (log-rank p=0.002). Conclusion Findings from this study highlight the importance of long-term follow-up of HNT patients for early detection of SPMs, increasing the chance of providing treatment with curative intent and improving patient outcomes and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.